Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OSU6162 in Bipolar Depression (OBID)
2024-517560-30-00Phase 2Authorised
- Sponsor
- University of Gothenburg
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of OSU-6162 in bipolar disorder (BD), sponsored by University of Gothenburg. Primary endpoint: Change in MADRS score. Planned start Oct 2024; status: authorised.
02
Drugs
OSU-6162
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on 2024-517560-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517560-30-00.